老虎证券

BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

Reuters
03-06
BRIEF-ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions

March 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O:

  • ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMS

  • ARS PHARMACEUTICALS INC - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025

  • ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM

  • ARS PHARMACEUTICALS INC: IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX

Source text: ID:nGNX3b0hhs

Further company coverage: SPRY.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10